Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
about
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the lMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTreatment of multiple myeloma bone disease: experimental and clinical data.Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter studyThe effects of proteasome inhibitors on bone remodeling in multiple myeloma.Engineered nanomedicine for myeloma and bone microenvironment targeting.Sotatercept in patients with osteolytic lesions of multiple myeloma.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialBone anabolic agents for the treatment of multiple myeloma.The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents.Effects of proteasome inhibitors on bone cancerBortezomib for previously untreated multiple myeloma.Prevention and treatment of myeloma bone disease.Bortezomib for the treatment of previously untreated multiple myeloma.Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents.The effects of bortezomib on bone disease in patients with multiple myeloma.Management of bone disease in multiple myeloma.Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.Myeloma and Bone Disease.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Emerging treatment approaches for myeloma-related bone disease.The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.The Proteasome and Myeloma-Associated Bone Disease.Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study groupFewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaAtypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma
P2860
Q26783464-849A300B-5240-46F4-9666-829C04FF64CAQ28082335-35C6B054-2AB6-4D58-80B4-DDCB9C28A381Q30868833-0E14155E-0336-4AB4-805B-536FE3965921Q33891364-1298C0D6-AEBC-4C38-B57C-776CCDF63771Q33918020-9EDB4840-2323-4780-A2FE-A56A11E66D5BQ33926003-34B1EE4D-02DA-428B-8B16-D9BDA05522E0Q35035011-F14EFF1F-4E6C-48E6-9A58-755E0313C231Q35141814-FCBB04C9-CE1F-440C-97CE-46E92D8704D9Q35603116-44B46D1F-CAA0-4174-BA46-2129D3D943B6Q35700723-499921A7-9BD4-43E2-AE64-E295A0C70F54Q36282399-C225AF09-47E2-42FE-967F-5EB7E749D06FQ36413352-6ECA9E6B-BAFE-4042-BA38-A68689241229Q36449801-FB327735-DF7C-41E5-8541-345AFB5D9657Q37281071-2D66F132-E79F-4DCF-8253-488E8248E3D5Q37937699-BE08DE0F-4D55-4563-A9C8-0586ADFA730DQ38039879-BE94A1C1-53A8-459A-B391-C680CF277F0DQ38096055-A65DF5C2-C431-4A64-9F9B-19B783D9CFC8Q38162876-7CE4187F-DE7C-476E-8042-DB21FB9BE4ABQ38163937-B6463341-1C08-45FA-80F7-1E8050E1822BQ38179039-B132C03F-148D-4DED-B7C0-5FE6B7C62767Q38189791-EFFAF266-D800-44CB-A717-B761CB16DF36Q38598342-C49ADE33-0308-460D-AE0C-8F4E9F6A2911Q38749233-06F2B085-B638-4BF3-81BA-91A56CFB4D9FQ39090721-300CB682-DD5E-45C2-A675-5EAF8EF4C856Q39212192-7D0B7338-3F7C-4971-AAAC-AFFADCD23111Q43759174-E7C0098F-CFDF-417E-91B7-FC30CB96350FQ47696279-7D45F233-DDCD-40DA-BC02-1C2ABBAF4CB1Q48314232-60871670-EA8C-473C-B68C-D9584441E9D2Q53142665-2D62C3EE-E484-449E-847F-186EFC9EFE98Q57904348-500AF4EE-27E8-416C-8708-FE503BB60A7AQ57904558-9E2FC154-E3C6-4FC9-99F7-774440400ECFQ58774460-62765E6C-D98C-49C4-AE91-EDEFD31B23D0
P2860
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Increased bone mineral density ...... methasone and zoledronic acid.
@en
Increased bone mineral density ...... methasone and zoledronic acid.
@nl
type
label
Increased bone mineral density ...... methasone and zoledronic acid.
@en
Increased bone mineral density ...... methasone and zoledronic acid.
@nl
prefLabel
Increased bone mineral density ...... methasone and zoledronic acid.
@en
Increased bone mineral density ...... methasone and zoledronic acid.
@nl
P2093
P356
P1433
P1476
Increased bone mineral density ...... methasone and zoledronic acid.
@en
P2093
D Christoulas
K Anargyrou
M Gavriatopoulou
P Kokkoris
P304
P356
10.1093/ANNONC/MDQ259
P577
2010-05-23T00:00:00Z